Market Overview

UPDATE: Wunderlich Initiates Cardiovascular Systems with Buy on Positive Outlook

Related CSII
Abaxis (ABAX) Soars: Stock Rises 9% - Tale of the Tape
Halozyme's Q1 Loss Widens - Analyst Blog

In a report published Friday, Wunderlich Securities analyst James Terwilliger initiated coverage on Cardiovascular Systems (NASDAQ: CSII) with a Buy rating and $24.00 price target.

In the report, Wunderlich Securities noted, “We are initiating coverage of Cardiovascular Systems, Inc. (CSII) with a Buy rating and a 12-month price target of $24.00, or 4.0x our fiscal 2015 revenue per share estimate of $6.08. CSII is a medical device company focused on minimally invasive treatments for vascular disease. CSII's initial focus is on the treatment of peripheral artery disease (PAD). CSII's products are catheter-based systems capable of treating a range of plaque types in leg arteries both above and below the knee. CSII intends to expand its catheter-based systems and move into the interventional coronary market. CSII has already sent its PMA application to the FDA to treat coronary artery disease. We assume regulatory approval and a coronary product launch in the U.S. in Q114.”

Cardiovascular Systems closed on Thursday at $20.79.

Latest Ratings for CSII

DateFirmActionFromTo
May 2014Bank of AmericaInitiates Coverage onBuy
Mar 2014NeedhamInitiates Coverage onStrong Buy
Feb 2014WunderlichTerminatesBuy

View More Analyst Ratings for CSII
View the Latest Analyst Ratings

Posted-In: James Terwilliger Wunderlich SecuritiesAnalyst Color Initiation Analyst Ratings

 

Related Articles (CSII)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional